Costos del tratamiento de erradicación del Helicobacter pylori en pacientes con úlcera péptica

Csendes, Attila; Burdiles, Patricio; Devaud, Nicolás; Artigas, Cristián.
Rev. chil. cir ; 56(3): 220-225, jun. 2004. tab
Artículo en Español | LILACS | ID: lil-394592

Documentos relacionados

  1. Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis.
  2. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
  3. Sequential Helicobacter pylori eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability.
  4. Sequential therapy versus standard triple drug therapy for eradication of Helicobacter pylori in patients with perforated duodenal ulcer following simple closure.
  5. Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates.
  6. A comparative analysis of univariate versus multivariate eco-friendly spectrophotometric manipulations for resolving severely overlapped spectra of vonoprazan and amoxicillin new combination.
  7. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence.
  8. Antibiotic resistance, heteroresistance, and eradication success of Helicobacter pylori infection in children.
  9. Management of Helicobacter pylori infection in paediatric patients in Europe: results from the EuroPedHp Registry.
  10. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.